Bristol Myers Squibb Raises 2026 Revenue Forecast as Newer Drugs Drive Q3 Growth
The Bristol Myers Squibb Q3 2026 results lift revenue guidance as newer drugs grow 12%. EPS fell on a $1.6 billion charge.
Baby Memorial Hospital Group Partners With DeepInfinity.AI to Scale Clinical AI
The Baby Memorial Hospital DeepInfinity AI partnership plans phased clinical and admin AI across nine hospitals. What is announced and what is unmeasured.
Molecular Partners Plans 44% Workforce Reduction to Focus on Radiotherapeutics
The Molecular Partners workforce reduction 2026 cuts up to 55 roles as the Swiss biotech focuses on targeted radiotherapy. Key facts and gaps.
Geron Discontinues Phase III Myelofibrosis Trial After Survival Goal Setback
Why the Geron IMpactMF trial discontinued: monitors judged the survival goal unlikely. Rytelo’s MDS approval is unaffected.
Biogen Q3 2026 Results: Revenue Rises 11% as Company Raises Earnings Guidance
The Biogen Q3 2026 results show revenue up 11% to $2.80 billion, but EPS fell and the guidance change was only at the low end.
Nucelion and Pandorum Partner on ₹17 Crore Eye-Therapy Research Programmes
The Nucelion Pandorum partnership backs two investigational eye programmes with a planned ₹16.97 crore outlay. What it covers and what is undisclosed.
Vera Health Raises $28.5 Million to Expand Its Clinical AI Search Platform
The Vera Health Series A funding of $28.5 million backs a clinical AI search engine. What it does, what is company-reported, and what is unproven.
Hundreds of UK GP Websites Hit by Healthcare Technology Provider Collapse
The UK GP websites outage October 2026 followed a technology provider’s collapse. What happened, what patients can do, and what is unconfirmed.
India Revises Prices of 543 Cancer-Medicine Brands: New Rates From November 9
The India cancer medicine price revision 2026 lowers MRPs for 543 brands from 9 November. What changed, what did not, and the caveats.
Mylan Blood Pressure Medication Recall: Affected Lots and FDA Classification
The Mylan telmisartan amlodipine recall covers five lots of 40 mg/5 mg tablets and is Class III. Here are the lots and what patients are advised.
SCHOTT Poonawalla Renamed SCHOTT Pharma India: What Changes?
The SCHOTT Pharma India name change replaces SCHOTT Poonawalla. The company says ownership, operations and customer commitments stay the same.